Browse > Article

Mutant Presenilin 2 Causes Abnormality in the Brain Lipid Profile in the Development of Alzheimer's Disease  

Nguyen, Hong Nga (College of Pharmacy and CBITRC, Chungbuk National University)
Son, Dong-Ju (College of Pharmacy and CBITRC, Chungbuk National University)
Lee, Jae-Woong (College of Pharmacy and CBITRC, Chungbuk National University)
Hwang, Dae-Youn (National Institute of Toxicological Research, Korea Food and Drug Administration)
Kim, Young-Kyu (National Institute of Toxicological Research, Korea Food and Drug Administration)
Cho, Jeong-Sik (National Institute of Toxicological Research, Korea Food and Drug Administration)
Lee, Ung-Soo (Department of Food and Biotechnology, Chungju National University)
Yoo, Hwan-Soo (College of Pharmacy and CBITRC, Chungbuk National University)
Moon, Dong-Cheul (College of Pharmacy and CBITRC, Chungbuk National University)
Oh, Ki-Wan (College of Pharmacy and CBITRC, Chungbuk National University)
Hong, Jin-Tae (College of Pharmacy and CBITRC, Chungbuk National University)
Publication Information
Archives of Pharmacal Research / v.29, no.10, 2006 , pp. 884-889 More about this Journal
Abstract
Mutation in the presenilin 2 (PS2mt) is known to be one of factors involved in the development of Alzheimer's disease (AD). It was recently revealed that an abnormality of lipid metabolism is a phenomenon occurring in AD. Therefore, the aim of this study was to investigate the potential relationship between the mutation of PS2 and alterations of the lipid profile within the brain. The results showed there increases in the levels of cholesterol, low density lipoprotein and triglyceride, but a decrease in the level of high density lipoprotein in brain tissues expressing mutant PS2. These findings indicated that PS2mt is involved in the abnormalities of the lipid profile, which could cause or result in the development of AD.
Keywords
Transgenic mice; Presenilin 2; Alzheimer's disease; Cholesterol; Triglyceride; HDL cholesterol; LDL cholesterol;
Citations & Related Records

Times Cited By Web Of Science : 3  (Related Records In Web of Science)
Times Cited By SCOPUS : 4
연도 인용수 순위
1 Fassbender, K., Simons, M., and Bergmann, C., Simvastatin strongly reduces levels of Alzheimer's disease $\beta$-amyloid peptides Ab42 and Ab40 in vitro and in vivo. Proc. Natl. Acad .Sci. USA, 98, 5856-5861 (2001)
2 Irizarry, M. C., Deng, A., Lleo, A., Berezovska, O., Von Arnim, C. A., Martin-Rehrmann, M., Manelli, A., LaDu, M. J., Hyman, B. T., and Rebeck, G. W., Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. J. Neurochem., 90, 1132-1143 (2004)   DOI   ScienceOn
3 Lee, S. Y., Hwang, D. Y., Kim, Y. K., Lee, J. W., Shin, I. C., Oh, K. W., Lee, M. K., Lim, J. S., Yoon, do. Y., Hwang, S. J., and Hong, J. T., PS2 mutation increases neuronal cell vulnerability to neurotoxicants through activation of caspase- 3 by enhancing of ryanodine receptor-mediated calcium release. FASEB J., 20,151-153 (2006)   DOI   ScienceOn
4 Simons, K. and Ikonen, E., How cells handle cholesterol. Science, 290, 1721-1726 (2000)   DOI   ScienceOn
5 Tan, Z. S., Seshadri, S., and Beiser, A., Plasma total cholesterol level as a risk factor for Alzheimer's disease: the Framingham study. Arch. Intern. Med., 163, 1053-1057 (2003)   DOI   ScienceOn
6 Wahrle, S., Das, P., and Nyborg, A. C., Cholesterol-dependent g-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis., 9, 11-23 (2002)   DOI   ScienceOn
7 Refolo, L. M., Pappolla, M. A., and La Francois, J., A cholesterol-lowering drug reduces b-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis., 8, 890-899 (2001)   DOI   ScienceOn
8 Ignatius, M. J., Gebicke-Harter, P. J., and Skene, J. H., Expression of apolipoprotein E during nerve degeneration and regeneration. Proc. Natl. Acad. Sci. U.S.A., 83, 1125-1129 (1986)
9 Buxbaum, J. D., Geoghagan, N. S., and Friedhoff, L. T., Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. J. Alzheimers Dis., 3, 221-229 (2001)   DOI
10 Koudinov, A. R., Berezov, T. T., and Kumar, A., Alzheimer's amyloid b interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Clin. Chim. Acta., 270, 75-84 (1998)   DOI   ScienceOn
11 Sawamura, N., Morishima-Kawashima, M., Waki, H., Kobayashi, K., Kuramochi, T., Frosch, M. P., Ding, K., Ito, M., Kim, T. W., Tanzi, R. E., Oyama, F., Tabira, T., Ando, S., and Ihara, Y., Mutant presenilin 2 transgenic mice. A large increase in the levels of Abeta 42 is presumably associated with the low density membrane domain that contains decreased levels of glycerophospholipids and sphingomyelin. J. Biol. Chem., 275, 27901-27908 (2000)
12 Janicki, S. and Monteiro, M. J., Increased apoptosis arising from increased expression of the Alzheimer's diseaseassociated presenilin-2 mutation (N141I). J. Cell Biol., 139, 485-495 (1997)   DOI
13 Galbete, J. L., Martin, T. R., Peressini, E., Modena, P., Bianchi, R., and Forloni, G., Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochem. J., 348, 307-313 (2000)   DOI
14 Pappolla, M. A., Bryant-Thomas, T. K., and Herbert, D., Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology, 61, 199- 205 (2003)   DOI   ScienceOn
15 De Sarno, P., Lesort, M., Bijur, G. N., Johnson, G. V., and Jope, R. S., Cholinergic- and stress-induced signaling activities in cells overexpressing wild-type and mutant presenilin-1. Brain Res., 903, 226-230 (2001)   DOI   ScienceOn
16 Deng, G., Pike, C. J., and Cotman, C. W., Alzheimer-associated presenilin-2 confers increased sensitivity to apoptosis in PC12 cells. FEBS Lett., 397, 50-54 (1996)   DOI   ScienceOn
17 Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S., and Drachman, D. A., Statins and the risk of dementia. Lancet, 356, 1627-1631 (2000)   DOI   ScienceOn
18 Refolo, L. M., Malester, B., La Francois, J., Bryant-Thomas, T., Wang, R., Tint, G. S., Sambamurti, K., Duff, K., and Pappolla, M. A., Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis., 7, 321-331 (2000)   DOI   ScienceOn
19 Diebold, K., Michel, G., Schweizer, J., Diebold-Dorsam, M., Fiehn, W., and Kohl, B., Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders- Pharmacopsychiatry, 31, 60-67 (1998)   DOI   ScienceOn
20 Hwang, D. Y., Chae, K. R., Kang, T. S., Hwang, J. H., Lim, C. H., Kang, H. K., Goo, J. S., Lee, M. R., Lim, H. J., Min, S. H., Cho, J. Y., Hong, J. T., Song, C. W., Paik, S. G., Cho, J. S., and Kim, Y. K., Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer's disease. FASEB J., 16, 805-813 (2002)   DOI   ScienceOn
21 Wellington, C. L., Cholesterol at the crossroads: Alzheimer's disease and lipid metabolism. Clin. Genet., 66, 1-16 (2004)   DOI   ScienceOn
22 Burns, M., Gaynor, K., and Olm, V., Presenilin redistribution associated with aberrant cholesterol transport enhances bamyloid production in vivo. J. Neurosci., 23, 5645-5649 (2003)   DOI
23 Runz, H., Rietdorf, J., Tomic, I., de Bernard, M., Beyreuther, K., Pepperkok, R., and Hartmann, T., Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J. Neurosci., 22, 1679-1689 (2002)   DOI
24 Subasinghe, S., Unabia, S., Barrow, C. J., Mok, S. S., Aguilar, M. I., and Small, D. H., Cholesterol is necessary both for the toxic effect of Abeta peptides on vascular smooth muscle cells and for Abeta binding to vascular smooth muscle cell membranes. J. Neurochem., 84, 471-479 (2003)   DOI   ScienceOn
25 Cutler, R. G., Kelly, J., Storie, K., Pedersen, W. A., Tammara, A., Hatanpaa, K., Troncoso, J. C., and Mattson, M. P., Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A., 101, 2070-2075 (2004)
26 Ehehalt, R., Keller, P., and Haass, C., Amyloidogenic processing of the Alzheimer b-amyloid precursor protein depends on lipid rafts. J. Cell Biol., 60, 113-123 (2003)
27 Shie, F. S., Jin, L. W., and Cook, D. G., Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport, 213, 455-459 (2002)
28 Michikawa, M., Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease? J. Neurosci. Res., 72, 141-146 (2003)   DOI   ScienceOn
29 Mori, M., Nakagami, H., Morishita, R., Mitsuda, N., Yamamoto, K., Yoshimura, S., Ohkubo, N., Sato, N., Ogihara, T., and Kaneda, Y., N141I mutant presenilin-2 gene enhances neuronal cell death and decreases bcl-2 expression. Life Sci., 70, 2567-2580 (2002)   DOI   ScienceOn
30 Koudinov, A. R., Berezov, T. T., and Koudinov, N. V., The levels of soluble amyloid beta in different high density lipoprotein subfractions distinguish Alzheimer's and normal aging cerebrospinal fluid: implication for brain cholesterol pathology? Neurosci. Lett., 314, 115-118 (2001)   DOI   ScienceOn